腾药品牌怎么样 申请店铺

我要投票 腾药在乌鸡白凤丸行业中的票数:249 更新时间:2025-02-05
腾药是哪个国家的品牌?「腾药」是 云南腾药制药股份有限公司 旗下著名品牌。该品牌发源于云南,由创始人赵丙贤在1990-06-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
腾药怎么样

腾冲,西南极边第一城,地处中缅边境,是中国古代南丝绸之路的必经之道。这里除了世人皆知的火山热海的奇特自然景观外,得天独厚的生物资源优势,也使之成为发展医药事业的天赐宝地。腾药历史,源远流长,早在北宋年间就有所记载,距今已有800多年。经历代药物学者和名医精研提炼,形成了其优良的品质和独特的风格。

云南省腾冲制药厂创建于上世纪五十年代,至今已有半个世纪的历史,而作为腾冲制药厂的发祥地,为纪念医药先贤“药王”孙思邈而修建的祠堂——“药王宫”则已有370多年的历史。这里荟萃了当地历史上不同流派的著名药店和医家精华,经过几代人的奋斗,早在上世纪七十年代就已步入全国重点中成药厂行列,在云南150多家医药工业企业中具有举足轻重的地位。尤其在产业结构、产品市场份额、专业技术力量、职工队伍素质等方面优势明显,被国家中医药管理局评为全国中药行业“优秀企业”金奖单位,连年被云南省政府评为“省级文明单位”和“先进管理企业”。目前生产的主要剂型有丸剂、冲剂、片剂、酊剂、散剂、糖浆剂、酒剂等七大剂型108个品种,年生产量达千吨以上,产品遍及省内外及东南亚地区,并享有良好的声誉。其中人参再造丸、大活络丸、六味地黄丸、感冒疏风片、藿香正气水等被列为云南省名优产品。

为追求领先的产品质量,改进管理水平,提升和打造“腾药”品牌,2002年下半年,药厂投资3500万元兴建现代化的GMP厂房,引进国际先进的制药机械更新生产线。目前,GMP厂房拥有七条现代化生产线,效率提高了3-4倍,并于2003年11月顺利通过了GMP认证。

为适应现代企业的要求,追求更高更快的发展,跨入新世纪,腾冲制药厂在现代企业制度的指导下,将走规模化和集团化的道路,促进新产品的开发和引进,充分发挥云南天然植物药的特色和优势,为云南医药产业的腾飞作出积极贡献!

Tengchong, the first city on the southwest pole, is located at the border between China and Myanmar, which is the only way along the ancient Southern Silk Road of China. In addition to the world's well-known unique natural landscape, the unique advantages of biological resources also make it a heaven-given treasure for the development of medicine. It has a long history. It was recorded as early as the Northern Song Dynasty. It has been more than 800 years since then. Through the refined research and refinement of modern medicine scholars and famous doctors, it has formed its excellent quality and unique style. Yunnan Tengchong pharmaceutical factory, founded in the 1950s, has a history of half a century. As the birthplace of Tengchong pharmaceutical factory, the ancestral hall "Yaowang Palace" built to commemorate Sun Simiao, the medicine sage, has a history of more than 370 years. It has gathered the essence of famous pharmacies and doctors in different schools in the local history. After several generations of struggle, it has entered the ranks of key Chinese patent medicine factories in the 70s of last century. It has a pivotal position in more than 150 pharmaceutical industrial enterprises in Yunnan. In particular, it has obvious advantages in industrial structure, product market share, professional and technical strength, staff quality, etc. it has been awarded the gold medal unit of "excellent enterprise" in the national traditional Chinese medicine industry by the State Administration of traditional Chinese medicine, and the "provincial civilized unit" and "advanced management enterprise" by the Yunnan provincial government for successive years. At present, there are 108 kinds of seven dosage forms, including pill, granule, tablet, tincture, powder, syrup, liquor, etc., with annual production of more than 1000 tons. The products are all over the province and Southeast Asia, and enjoy a good reputation. Among them, Renshen Zaizai Wan, Dahuoluo Wan, Liuwei Dihuang Wan, Ganmao Shufeng tablet, Huoxiang Zhengqi water are listed as famous and excellent products in Yunnan Province. In order to pursue the leading product quality, improve the management level, enhance and create the "tengyao" brand, in the second half of 2002, the pharmaceutical factory invested 35 million yuan to build a modern GMP plant, and introduced the international advanced pharmaceutical machinery to update the production line. At present, GMP plant has seven modern production lines, the efficiency has increased 3-4 times, and passed GMP certification in November 2003. In order to meet the requirements of modern enterprises, pursue higher and faster development, and stride into the new century, under the guidance of modern enterprise system, Tengchong pharmaceutical factory will take the road of scale and collectivization, promote the development and introduction of new products, give full play to the characteristics and advantages of Yunnan natural plant medicine, and make positive contributions to the take-off of Yunnan pharmaceutical industry!

本文链接: https://brand.waitui.com/10f3ee07f.html 联系电话:08755133464

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

2小时前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

2小时前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

2小时前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

2小时前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

2小时前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询